Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab
| Autor: | Hyung-Don Kim, Yoon-Koo Kang, Min-Hee Ryu, Hyungwoo Cho, Hyung Eun Lee |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 First line Natural Killer Cell Activity Immunology Treatment outcome Cell Stomach Neoplasms Trastuzumab Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Immunology and Allergy Normal range Platinum business.industry Cancer Middle Aged Advanced gastric cancer Prognosis medicine.disease Killer Cells Natural medicine.anatomical_structure Female business medicine.drug |
| Zdroj: | Cancer Immunology, Immunotherapy. 71:829-838 |
| ISSN: | 1432-0851 0340-7004 |
| DOI: | 10.1007/s00262-021-03035-x |
| Popis: | We aimed to evaluate the prognostic value of natural killer (NK) cell activity for patients with HER2 + advanced gastric cancer (AGC) treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab. Forty-one patients with HER2 + AGC who received fluoropyrimidine–platinum doublet plus trastuzumab as first-line treatment were prospectively enrolled. NK cell activity was evaluated using the NK Vue®. The median age was 63.5 years, and 31 patients (75.6%) were male. Patients with low baseline NK cell activity (≤ median, n = 21) were associated worse progression-free survival (PFS) and overall survival (OS) compared with patients with high baseline NK cell activity (> median, n = 20) with a median PFS of 4.21 vs. 9.53 months (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink